80岁以上急性缺血性卒中患者的阿替普酶治疗:个体患者数据的汇总分析
本研究汇总7项随机对照试验的个体患者数据及欧洲SITS-UTMOST登记数据库,评估阿替普酶(0.9 mg/kg)对80岁以上急性缺血性卒中患者的获益-风险特征。结果显示,80岁以上患者接受阿替普酶后良好功能结局比例高于安慰剂(19.1% vs 13.1%,P=0.0109),90天死亡率相似(29.5% vs 30.2%,P=0.8382),支持在符合其他监管标准的前提下放宽年龄上限。
要点
- 80岁以上患者接受阿替普酶良好结局比例高于安慰剂,死亡率无显著差异
- 阿替普酶获益与年龄无关(P=0.7383),应基于个体获益-风险评估
- 常规实践中阿替普酶患者良好结局达43.2%,与随机对照试验结果一致
核心结论
- 80岁以上急性缺血性卒中患者按其他监管标准使用阿替普酶具有正向获益-风险特征。
- 阿替普酶治疗应基于个体获益-风险评估,而非仅凭年龄限制。
研究设计与样本
- 汇总7项阿替普酶(0.9 mg/kg)对比安慰剂或开放对照的随机对照试验个体患者数据,并结合欧洲SITS-UTMOST登记数据库进行分析。
- 评估全随机对照试验人群、登记人群及按年龄(≤80岁或>80岁)划分且符合现有欧洲监管标准(不含年龄上限)的亚组。
主要发现
- 随机对照试验中符合现有欧洲监管标准的≤80岁患者90天死亡率为246/2405(10.2%),>80岁患者为307/1028(29.9%)。
- >80岁患者中,阿替普酶组良好卒中结局(改良Rankin量表0-1分)为99/518(19.1%),安慰剂组为67/510(13.1%),P=0.0109。
- >80岁患者中,阿替普酶组90天死亡率为153/518(29.5%),安慰剂组为154/510(30.2%),P=0.8382。
- 全随机对照试验人群中,阿替普酶分配后良好卒中结局的比值比与年龄无关(P=0.7383)。
关键数值与推荐
- 良好功能结局定义为改良Rankin量表第90天评分0-1分或牛津残障评分第180天评分0-1分。
- 阿替普酶剂量为0.9 mg/kg。
- >80岁患者阿替普酶组良好结局19.1% vs 安慰剂组13.1%,P=0.0109。
- >80岁患者阿替普酶组90天死亡率29.5% vs 安慰剂组30.2%,P=0.8382。
- 阿替普酶获益与年龄交互作用P=0.7383。
临床怎么用
- 对80岁以上急性缺血性卒中患者,在符合其他监管标准的前提下可考虑使用阿替普酶(0.9 mg/kg)。
- 治疗决策应基于个体获益-风险评估,不应仅因年龄超过80岁而排除阿替普酶。
- 常规实践中的结局数据支持随机对照试验结果,可增强临床信心。
局限性
- 本研究为汇总分析,非预设前瞻性研究,可能存在异质性。
- 登记数据库数据可能存在报告偏倚和混杂因素。
- 原文未报告亚组外的其他年龄分层或长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: Expert guidelines specify no upper age limit for alteplase for thrombolysis of acute ischemic stroke (AIS) but, until recently, European regulatory criteria restricted its use to patients aged 18 to 80 years. We performed pooled analyses of randomized controlled trial (RCT) and registry data to evaluate the benefit-risk profile of alteplase for AIS among patients aged >80 years to support a regulatory application to lift the upper age restriction. METHODS: Individual patient data were evaluated from 7 randomized trials of alteplase (0.9 mg/kg) versus placebo or open control for AIS, and the European SITS-UTMOST registry database. Clinical outcomes, including good functional outcome (score 0-1, modified Rankin Scale day 90 or Oxford Handicap Score day 180), were evaluated in the full RCT and registry populations, and specified age-based subgroups (≤80 or >80 years) who met existing European regulatory criteria for alteplase, excluding upper age restriction. RESULTS: Regardless of treatment allocation, 90-day mortality was lower among RCT patients aged ≤80 versus >80 years who otherwise met existing European regulatory criteria (246/2405 [10.2%] versus 307/1028 [29.9%], respectively). Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P=0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P=0.8382). The odds of a good stroke outcome following alteplase allocation in the full RCT population were independent of age (P=0.7383). Good stroke outcome was reported for almost half (4821/11 169 [43.2%]) of the patients who received alteplase in routine practice. Outcomes in routine practice supported those achieved in RCTs. CONCLUSIONS: Alteplase for AIS has a positive benefit-risk profile among patients aged >80 years when administered according to other regulatory criteria. Alteplase for AIS should be evaluated on an individual benefit-risk basis.
引用
- Bluhmki E, Danays T, Biegert G, et al. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data. Stroke. 2020. PMID: 32611284. doi:10.1161/STROKEAHA.119.028396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。